Search results for "Carbamates"

showing 4 items of 94 documents

Glutathione-dependent resistance of the European eel Anguilla anguilla to the herbicide molinate

2001

Eels of species Anguilla anguilla were exposed to 5/4 LC50 (41.8 mg/l) of the herbicide molinate for 96 h in a time to death (TTD) test. Glutathione content (GSx, GSH, GSSG), glutathione reductase (GR) and gamma-glutamyl transpeptidase (gamma-GT) activities were determined in the liver and muscle tissues of dead and surviving (intoxicated) animals and compared to control values (non-exposed eels). TTD was positively correlated to hepatic GSH, GSH:GSSG ratio, hepatic and muscular GR, but negatively correlated to muscular GSH, which was severely depleted. Furthermore, glutathione and enzyme activities were intercorrelated, especially GSH and GR. These results indicate that eels which were abl…

medicine.medical_specialtyEnvironmental EngineeringHealth Toxicology and MutagenesisGlutathione reductaseDrug ResistanceMedizinReductasemedicine.disease_causechemistry.chemical_compoundAnguillidaeThiocarbamatesInternal medicinemedicineEnvironmental ChemistryAnimalsMuscle Skeletalchemistry.chemical_classificationbiologyHerbicidesPublic Health Environmental and Occupational HealthGeneral MedicineGeneral ChemistryGlutathioneAzepinesgamma-Glutamyltransferasebiology.organism_classificationAnguillaPollutionGlutathioneEndocrinologyEnzymeGlutathione ReductasechemistryLiverToxicityCarbamatesHomeostasisOxidative stress
researchProduct

Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction

2013

Endocannabinoids are important regulators of organ homeostasis. Although their role in systemic vasculature has been extensively studied, their impact on pulmonary vessels remains less clear. Herein, we show that the endocannabinoid anandamide (AEA) is a key mediator of hypoxic pulmonary vasoconstriction (HPV) via fatty acid amide hydrolase (FAAH)-dependent metabolites. This is underscored by the prominent vasoconstrictive effect of AEA on pulmonary arteries and strongly reduced HPV in FAAH(-/-) mice and wild-type mice upon pharmacological treatment with FAAH inhibitor URB597. In addition, mass spectrometry measurements revealed a clear increase of AEA and the FAAH-dependent metabolite arac…

medicine.medical_specialtyPolyunsaturated Alkamidesmedicine.medical_treatmentHypertension PulmonaryBlotting WesternMyocytes Smooth MuscleArachidonic AcidsBiologyAmidohydrolaseschemistry.chemical_compoundMiceFatty acid amide hydrolaseInternal medicineHypoxic pulmonary vasoconstrictionmedicineAnimalsHypoxiaLungDNA PrimersMice KnockoutAnalysis of VarianceMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionAnandamideHypoxia (medical)URB597Biological Sciencesmedicine.diseaseEndocannabinoid systemPulmonary hypertensionImmunohistochemistryEndocrinologynervous systemchemistryVasoconstrictionBenzamideslipids (amino acids peptides and proteins)CannabinoidCarbamatesmedicine.symptompsychological phenomena and processesChromatography LiquidEndocannabinoidsSignal Transduction
researchProduct

Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repagl…

2004

The 11 C-labeled sulfonylurea receptor 1 (SUR1) ligand (S)-2-(( 11 C)methoxy)-4-(3-methyl-1-(2-piperidine-1-yl-phenyl)- butyl-carbamoyl)-benzoic acid (( 11 C)methoxy-repaglinide) was synthesized in an overall radiochemical yield of 35% after 55 min with a radiochemical purity higher than 99%. This compound is considered for the noninvasive investigation of the SUR1 receptor status of pancreatic b-cells by positron emission tomography (PET) in the context of type 1 and type 2 diabetes. The specific activity was 40-70 GBq/lmol. In vitro testing of the nonradioactive methoxy-repaglinide was performed to characterize the affinity for binding to the human SUR1 isoform. Methoxy-repaglinide induce…

medicine.medical_specialtyPotassium Channelsmedicine.medical_treatmentReceptors DrugClinical BiochemistryPharmaceutical ScienceType 2 diabetesIn Vitro TechniquesSulfonylurea ReceptorsBiochemistryBenzoatesBinding CompetitiveIslets of LangerhansPiperidinesDiabetes mellitusInternal medicineDrug DiscoveryInsulin SecretionmedicineAnimalsHumansInsulinCarbon RadioisotopesPotassium Channels Inwardly RectifyingMolecular BiologyIC50Type 1 diabetesChemistryInsulinOrganic ChemistryStereoisomerismmedicine.diseaseRepaglinideLigand (biochemistry)RatsEndocrinologyPositron-Emission TomographyCOS CellsMolecular MedicineSulfonylurea receptorATP-Binding Cassette TransportersCarbamatesRadiopharmaceuticalsHydroxybenzoate Ethersmedicine.drugBioorganicmedicinal chemistry letters
researchProduct

CHF2819: Pharmacological profile of a novel acetylcholinesterase inhibitor

2002

CHF2819 is a novel orally active acetylcholinesterase inhibitor (AChEI) developed for the treatment of Alzheimer's disease (AD). CHF2819 is a selective inhibitor of AChE, it is 115 times more potent against this enzyme than against butyrylcholinesterase (BuChE). Moreover, CHF2819 is more selective for inhibition of central (brain) AChE than peripheral (heart) AChE. In vivo CHF2819, 0.5, 1.5, and 4.5 mg/kg p.o., significantly and in dose-dependent manner increased acetylcholine (ACh) levels in hippocampus of young adult rats. Moreover, aging animals, with lower basal ACh levels than young adult rats, also exhibit a marked increase in hippocampal levels of this neurotransmitter after administ…

medicine.medical_specialtymedicine.drug_classPhenylcarbamatesPharmacologyHippocampusArticleCyclic N-Oxideschemistry.chemical_compoundNeurochemicalAlzheimer DiseaseDopamineInternal medicinemedicineAnimalsBiogenic MonoaminesAmino AcidsNeurotransmitterButyrylcholinesteraseCholinesterasePharmacologybiologybusiness.industryGlutamate receptoracetylcholinesterase inhibitors; alzheimer's disease; amino acids; chf2819; ganstigmine; neurotransmitters; rat hippocampusAcetylcholineRatsNeuropsychology and Physiological PsychologyEndocrinologyAcetylcholinesterase inhibitorchemistrybiology.proteinCarbamatesCholinesterase InhibitorsbusinessAcetylcholinemedicine.drug
researchProduct